PharmaEssentia Gets Nod for Advanced Trial of Blood Cancer Drug

MT Newswires Live

2025/03/27

PharmaEssentia (TPE:6446) secured approval from China's National Medical Products Administration to proceed with the phase three clinical trial of its drug Ropeginterferon alfa-2b (P1101).

The drug is indicated for patients with pre-fibrotic/early primary myelofibrosis (PMF) or overt PMF at low or intermediate-1 risk, according to a Taiwan Exchange filing.

The trial will assess the efficacy and safety of the drug, which is already approved for Polycythemia Vera (PV) in over 40 countries.

The pharmaceutical company expects patient recruitment to be completed in 2025, it added.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2522031519"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2522031519\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2522031519?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-27 13:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2522031519","market":"fut","top_or_hot":-1,"title":"PharmaEssentia Gets Nod for Advanced Trial of Blood Cancer Drug","media":"MT Newswires Live","content":"<html><body><p> PharmaEssentia (TPE:6446) secured approval from China's National Medical Products Administration to proceed with the phase three clinical trial of its drug Ropeginterferon alfa-2b (P1101).</p><p>The drug is indicated for patients with pre-fibrotic/early primary myelofibrosis (PMF) or overt PMF at low or intermediate-1 risk, according to a Taiwan Exchange filing.</p><p>The trial will assess the efficacy and safety of the drug, which is already approved for Polycythemia Vera (PV) in over 40 countries.</p><p>The pharmaceutical company expects patient recruitment to be completed in 2025, it added.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PharmaEssentia Gets Nod for Advanced Trial of Blood Cancer Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPharmaEssentia Gets Nod for Advanced Trial of Blood Cancer Drug\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-03-27 13:23</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> PharmaEssentia (TPE:6446) secured approval from China's National Medical Products Administration to proceed with the phase three clinical trial of its drug Ropeginterferon alfa-2b (P1101).</p><p>The drug is indicated for patients with pre-fibrotic/early primary myelofibrosis (PMF) or overt PMF at low or intermediate-1 risk, according to a Taiwan Exchange filing.</p><p>The trial will assess the efficacy and safety of the drug, which is already approved for Polycythemia Vera (PV) in over 40 countries.</p><p>The pharmaceutical company expects patient recruitment to be completed in 2025, it added.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK6522","symbol_name":"化石燃料股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2522031519","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2522031519","pubTimestamp":1743053025,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"PharmaEssentia  secured approval from China's National Medical Products Administration to proceed with the phase three clinical trial of its drug Ropeginterferon alfa-2b .The drug is indicated for patients with pre-fibrotic/early primary myelofibrosis  or overt PMF at low or intermediate-1 risk, according to a Taiwan Exchange filing.The trial will assess the efficacy and safety of the drug, which is already approved for Polycythemia Vera  in over 40 countries.The pharmaceutical company expects patient recruitment to be completed in 2025, it added.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK6522":"化石燃料股","BLZ.SI":"爱文思控股","IE00B66KJ199.SGD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY  \" A\" (SGD) ACC","IE00B7SZL793.SGD":"Legg Mason Royce - US Small Cap Opportunity A Acc SGD-H","IE00B19Z4B17.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) ACC","BK6088":"石油天然气设备与服务","PMF":"太平洋投资管理市政收益基金","AEIS":"先进能源工业公司","BK4157":"电子设备和仪器","IE0031619046.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) INC"},"translate_title":"PharmaEssentia血癌药物高级试验获得认可","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AEIS":1,"BLZ.SI":1,"PMF":1},"content_text":"PharmaEssentia (TPE:6446) secured approval from China's National Medical Products Administration to proceed with the phase three clinical trial of its drug Ropeginterferon alfa-2b (P1101).The drug is indicated for patients with pre-fibrotic/early primary myelofibrosis (PMF) or overt PMF at low or intermediate-1 risk, according to a Taiwan Exchange filing.The trial will assess the efficacy and safety of the drug, which is already approved for Polycythemia Vera (PV) in over 40 countries.The pharmaceutical company expects patient recruitment to be completed in 2025, it added.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}